About: Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$19.70 (+0.41%)
NEU ASX Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Ltd share price
Atividade de preço de NEU
Último preço
$ 19,700
Variação (24h)
0,08 AUD (0,41%)
Volume
304.81K
Volume (média 4 sem.)
-
Abertura
$ 20,00
Variação do dia
$ 19,34 - $ 20,15
Fechamento anterior
$ 19,62
Último negócio
21 Oct, 5:30 am GMT+0
Atrasado
21 Oct, 5:30 am GMT+0
NEU price performance
Atrasado
21 Oct, 5:30 am GMT+0
quote.marketSignals